Showing results (161-170 of 199) with videos related to

Sort By:
Pageof 20
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyJeong Heo, Caroline J Breitbach, Anne Moon, et al.
Cancer Research|February 9, 2013
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humansCaroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 26, 2012
ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeuticJulia L Rintoul, Chantal G Lemay, Lee-Hwa Tai, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 15, 2010
A high-throughput pharmacoviral approach identifies novel oncolytic virus sensitizersJean-Simon Diallo, Fabrice Le Boeuf, Frances Lai, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2023
Engineering Rapalog-Inducible Genetic Switches Based on Split-T7 Polymerase to Regulate Oncolytic Virus-Driven Production of Tumour-Localized IL-12 for Anti-Cancer ImmunotherapyNikolas T Martin, Mathieu J F Crupi, Zaid Taha, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2008
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisThi Lien-Anh Nguyên, Hesham Abdelbary, Meztli Arguello, et al.
Molecular Therapy. Methods & Clinical Development|October 12, 2023
A T cell-targeted multi-antigen vaccine generates robust cellular and humoral immunity against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Rida Gill, et al.
Scientific Reports|May 27, 2016
First-in-class small molecule potentiators of cancer virotherapyMark H Dornan, Ramya Krishnan, Andrew M Macklin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 22, 2011
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancersKelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, et al.
Membranes|September 3, 2020
Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein Transmembrane Domain to Receptor-Binding Domain Induces TrimerizationTaha Azad, Ragunath Singaravelu, Mathieu J F Crupi, et al.
Pageof 20